ATGC Co., Ltd.
Quick facts
Marketed products
- Xeomin® · Neurology / Aesthetics
Xeomin is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
Phase 3 pipeline
- ATGC-110 · Oncology
ATGC-110 is a small molecule that targets the PD-1 receptor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: